High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
暂无分享,去创建一个
Ron O. Dror | Brian K. Kobilka | Cheng Zhang | Daniel Palmer | William I. Weis | David E. Shaw | R. Dror | D. Shaw | W. Weis | B. Kobilka | J. Fung | S. Coughlin | Daniel H Arlow | Hillary F. Green | A. Pandey | Shaun R. Coughlin | Daniel H. Arlow | Anjali Pandey | Yoga Srinivasan | Juan Jose Fung | Yaowu Zheng | Yaowu Zheng | Y. Srinivasan | D. Palmer | Cheng Zhang
[1] V. Cherezov,et al. Crystallizing membrane proteins using lipidic mesophases , 2009, Nature Protocols.
[2] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[3] Vincent B. Chen,et al. Correspondence e-mail: , 2000 .
[4] A. Herz,et al. Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. , 1990, Molecular pharmacology.
[5] R. Dror,et al. Gaussian split Ewald: A fast Ewald mesh method for molecular simulation. , 2005, The Journal of chemical physics.
[6] V. Wheaton,et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.
[7] R. Stevens,et al. Structure of the human k-opioid receptor in complex with JDTic , 2012 .
[8] Hugh Rosen,et al. Crystal Structure of a Lipid G Protein–Coupled Receptor , 2012, Science.
[9] Marjorie M Harding. Metal-ligand geometry relevant to proteins and in proteins: sodium and potassium. , 2002, Acta crystallographica. Section D, Biological crystallography.
[10] B. Kobilka,et al. Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. , 1993, The Journal of biological chemistry.
[11] S. Coughlin,et al. Protease‐activated receptors in hemostasis, thrombosis and vascular biology , 2005, Journal of thrombosis and haemostasis : JTH.
[12] J. Welsh,et al. Determinants of Thrombin Receptor Cleavage. RECEPTOR DOMAINS INVOLVED, SPECIFICITY, AND ROLE OF THE P3 ASPARTATE (*) , 1995, The Journal of Biological Chemistry.
[13] S. Coughlin,et al. The Cytoplasmic Tails of Protease-activated Receptor-1 and Substance P Receptor Specify Sorting to Lysosomes versusRecycling* , 1999, The Journal of Biological Chemistry.
[14] B. Kobilka,et al. Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitization of a G protein-coupled receptor. , 1994, The Journal of biological chemistry.
[15] V. Wheaton,et al. Domains specifying thrombin–receptor interaction , 1991, Nature.
[16] A. IJzerman,et al. Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. , 2000, Biochemical pharmacology.
[17] S. Coughlin,et al. Thrombin signalling and protease-activated receptors , 2000, Nature.
[18] Rob Leurs,et al. Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. , 2007, Annual review of pharmacology and toxicology.
[19] J. Chen,et al. Thrombin receptor activation. Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. , 1994, The Journal of biological chemistry.
[20] A. Vliet,et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects , 2011, European Journal of Clinical Pharmacology.
[21] J. Baleja,et al. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. , 2003, Chemistry & biology.
[22] Aashish Manglik,et al. Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.
[23] S. Coughlin,et al. Role of the Thrombin Receptor's Cytoplasmic Tail in Intracellular Trafficking , 1996, The Journal of Biological Chemistry.
[24] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[25] S. Coughlin,et al. Termination of signaling by protease-activated receptor-1 is linked to lysosomal sorting. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] Bertil Hille. G protein-coupled receptor , 2009, Scholarpedia.
[27] Albert C. Pan,et al. Pathway and mechanism of drug binding to G-protein-coupled receptors , 2011, Proceedings of the National Academy of Sciences.
[28] C W Turck,et al. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. , 1994, Biochemistry.
[29] M. Fregly,et al. Sodium and Potassium , 1914, The Dental register.
[30] K. Lindorff-Larsen,et al. How robust are protein folding simulations with respect to force field parameterization? , 2011, Biophysical journal.
[31] C. A. Guyer,et al. An aspartate conserved among G-protein receptors confers allosteric regulation of alpha 2-adrenergic receptors by sodium. , 1990, The Journal of biological chemistry.
[32] R. Stevens,et al. GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.
[33] F. Cohen,et al. Mechanisms of Thrombin Receptor Agonist Specificity , 1995, The Journal of Biological Chemistry.
[34] S. Coughlin,et al. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis , 2010, Proceedings of the National Academy of Sciences.
[35] S. Rasmussen,et al. Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.
[36] Marc P. Bonaca,et al. Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.
[37] M. García-López,et al. Thrombin-activated receptors: promising targets for cancer therapy? , 2010, Current medicinal chemistry.
[38] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[39] L. Limbird,et al. The role of a conserved inter-transmembrane domain interface in regulating alpha(2a)-adrenergic receptor conformational stability and cell-surface turnover. , 2001, Molecular pharmacology.
[40] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[41] C. Esmon,et al. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. , 1991, The Journal of biological chemistry.
[42] K. Neve,et al. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. , 2001, Molecular pharmacology.
[43] L. Pardo,et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.
[44] T. Schwartz,et al. Molecular mechanism of 7TM receptor activation--a global toggle switch model. , 2006, Annual review of pharmacology and toxicology.
[45] Alexander D. MacKerell,et al. CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..
[46] M. Hollenberg,et al. Targeting proteinase-activated receptors: therapeutic potential and challenges , 2012, Nature Reviews Drug Discovery.
[47] R. Scarborough,et al. Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. , 2000, Molecular pharmacology.
[48] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[49] J. Kutok,et al. Identification of a novel thrombin receptor sequence required for activation-dependent responses. , 1994, Blood.
[50] Alexander D. MacKerell,et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. , 2010, The journal of physical chemistry. B.
[51] Gianni De Fabritiis,et al. Induced Effects of Sodium Ions on Dopaminergic G-Protein Coupled Receptors , 2010, PLoS Comput. Biol..
[52] C. Turck,et al. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface , 1994, Nature.
[53] S. Coughlin,et al. Separate Signals for Agonist-independent and Agonist-triggered Trafficking of Protease-activated Receptor 1* , 1998, The Journal of Biological Chemistry.
[54] Mark E. Tuckerman,et al. Reversible multiple time scale molecular dynamics , 1992 .
[55] M. Caffrey. Crystallizing membrane proteins for structure determination: use of lipidic mesophases. , 2009, Annual review of biophysics.
[56] H. Schiöth,et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.
[57] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[58] Alexander D. MacKerell,et al. Extending the treatment of backbone energetics in protein force fields: Limitations of gas‐phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations , 2004, J. Comput. Chem..
[59] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[60] K. Fahmy,et al. Protonation states of membrane-embedded carboxylic acid groups in rhodopsin and metarhodopsin II: a Fourier-transform infrared spectroscopy study of site-directed mutants. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[61] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[62] W. Greenlee,et al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. , 2005, Journal of medicinal chemistry.